Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, Minghao Song, Ekaterina Pestova, Rupinder Kular, Carolyn Mullen, Zheng Zha, Xin Lu, Erica Gomez, Anahita Bhathena, David Maag, Priya Kumthekar, Hui K Gan, Andrew M Scott, Maria Guseva, Kyle D Holen, Peter J Ansell, Martin J van den Bent
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2019
Awarded by AbbVie, Inc.
Awarded by NCI Cancer Center Support Grant
Awarded by ICTS/CTSA from the National Center for Research Resources (NCRR), a component of the NIH
Awarded by NCI
AbbVie, Inc. provided financial support for this study (NCT01800695) and participated in the design, study conduct, analysis and interpretation of the data, as well as the writing, review, and approval of the manuscript. All authors were involved in the data gathering, analysis, review, interpretation, and manuscript preparation and approval. The authors and AbbVie would like to thank patients and their families/caregivers; study investigators and staff; Mrinal Y. Shah, PhD for medical writing support, and Yan Sun, PhD for statistical support, both of AbbVie, Inc.; and the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for help with genomic analysis. The Center is partially supported by NCI Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant #UL1RRO24992 from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. A.B. Lassman was supported in part by Voices Against Brain Cancer, the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian Hospital, and grants P30CA013696 and UG1CA189960 from the NCI.